Drug Trial Radar · NCT04618211
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Feb 3, 2021
Primary completion
Sep 23, 2022
Study completion Mar 1, 2023
Sponsor
- Lead sponsor
- Pharvaris Netherlands B.V.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.
Conditions
- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- C1 Esterase Inhibitor Deficiency
- C1 Inhibitor Deficiency
Interventions
DeucrictibantDrug
deucrictibant soft capsules for oral use
PlaceboDrug
Matching placebo capsules for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatmentTime frame: Assessed from pre-treatment to 4 hours post-treatment
Locations
36 sites in 13 countries. Site status is shown where the registry gives one.
Study site
Birmingham, Alabama
Study site
Paradise Valley, Arizona
Study site
San Diego, California
Study site
Santa Monica, California
Study site
Walnut Creek, California
Study site
Chevy Chase, Maryland
Study site
St Louis, Missouri
Study site
Hershey, Pennsylvania
Study site
Sofia, Bulgaria
Study site
Edmonton, Alberta, Canada
Study site
Ottawa, Ontario, Canada
Study site
Toronto, Ontario, Canada
Study site
Montreal, Quebec, Canada
Study site
Québec, Quebec, Canada
Study site
Brno, Czechia
Study site
Hradec Králové, Czechia
Study site
Grenoble, France
Study site
Montpellier, France
Study site
Paris, France
Study site
Berlin, Germany
Study site
Dresden, Germany
Study site
Frankfurt, Germany
Study site
Mainz, Germany
Study site
Ulm, Germany
Study site
Budapest, Hungary
Study site
Ashkelon, Israel
Study site
Haifa, Israel
Study site
Tel Aviv, Israel
Study site
Monserrato, Italy
Study site
Naples, Italy
Study site
Amsterdam, Netherlands
Study site
Krakow, Poland
Study site
Barcelona, Spain
Study site
Madrid, Spain
Study site
Brighton, United Kingdom
Study site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.